Literature DB >> 30822617

Highly active multiple sclerosis: An update.

Cindy Díaz1, Luis Alfonso Zarco2, Diego M Rivera3.   

Abstract

Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide. It is characterized by brain and spinal cord involvement. There are the relapsing remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS) phenotypes. There is a subgroup of RRMS patients who have a more aggressive disease course marked by a rapid accumulation of physical and cognitive deficit, despite treatment with 1 or more disease modifying drugs (DMTs). In the past, this disease phenotype was called "aggressive" MS (AMS); it is now called highly active MS (HAMS). It is generally agreed that the severe nature of this phenotype requires different treatment decisions. Unfortunately, there is no consensus on the definition of AMS or the treatment algorithm. In this article we review HAMS in relation to its definition and the treatments available.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Highly active multiple sclerosis; Multiple sclerosis; Review

Mesh:

Year:  2019        PMID: 30822617     DOI: 10.1016/j.msard.2019.01.039

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  21 in total

1.  Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis.

Authors:  E C D Gonçalves; V Lieberknecht; V V Horewicz; B D Rabelo; F A Felipetti; A L S Rodrigues; D F Martins; R C Dutra
Journal:  Mol Neurobiol       Date:  2021-08-25       Impact factor: 5.590

2.  Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis.

Authors:  Agnieszka Staśkiewicz; Michael Quagliata; Feliciana Real-Fernandez; Francesca Nuti; Roberta Lanzillo; Vincenzo Brescia-Morra; Hendrik Rusche; Michal Jewginski; Alfonso Carotenuto; Diego Brancaccio; Rina Aharoni; Ruth Arnon; Paolo Rovero; Rafal Latajka; Anna Maria Papini
Journal:  Front Chem       Date:  2022-06-20       Impact factor: 5.545

Review 3.  Involvement of the Intestinal Microbiota in the Appearance of Multiple Sclerosis: Aloe vera and Citrus bergamia as Potential Candidates for Intestinal Health.

Authors:  Jessica Maiuolo; Vincenzo Musolino; Micaela Gliozzi; Cristina Carresi; Federica Scarano; Saverio Nucera; Miriam Scicchitano; Francesca Oppedisano; Francesca Bosco; Roberta Macri; Ernesto Palma; Carolina Muscoli; Vincenzo Mollace
Journal:  Nutrients       Date:  2022-06-29       Impact factor: 6.706

4.  Reproducibility of Lesion Count in Various Subregions on MRI Scans in Multiple Sclerosis.

Authors:  Bence Bozsik; Eszter Tóth; Ilona Polyák; Fanni Kerekes; Nikoletta Szabó; Krisztina Bencsik; Péter Klivényi; Zsigmond Tamás Kincses
Journal:  Front Neurol       Date:  2022-05-10       Impact factor: 4.086

5.  Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Authors:  Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn
Journal:  Syst Rev       Date:  2022-07-01

6.  Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.

Authors:  Ofir Zmira; Alex I Halpern; Lital Abraham; Anat Achiron
Journal:  Acta Neurol Belg       Date:  2020-05-23       Impact factor: 2.396

Review 7.  Expert opinion on the use of cladribine tablets in clinical practice.

Authors:  Per Soelberg Sørensen; Diego Centonze; Gavin Giovannoni; Xavier Montalban; Daniel Selchen; Patrick Vermersch; Heinz Wiendl; Bassem Yamout; Hashem Salloukh; Peter Rieckmann
Journal:  Ther Adv Neurol Disord       Date:  2020-06-24       Impact factor: 6.570

8.  Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.

Authors:  Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

9.  Multiple sclerosis.

Authors:  Shilpa Klocke; Nicole Hahn
Journal:  Ment Health Clin       Date:  2019-11-27

Review 10.  Bile Acid Signaling in Neurodegenerative and Neurological Disorders.

Authors:  Stephanie M Grant; Sharon DeMorrow
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.